Minimal sufficient balance—a new strategy to balance baseline covariates and preserve randomness of treatment allocation

In many clinical trials, baseline covariates could affect the primary outcome. Commonly used strategies to balance baseline covariates include stratified constrained randomization and minimization. Stratification is limited to few categorical covariates. Minimization lacks the randomness of treatment allocation. Both apply only to categorical covariates. As a result, serious imbalances could occur in important baseline covariates not included in the randomization algorithm. Furthermore, randomness of treatment allocation could be significantly compromised because of the high proportion of deterministic assignments associated with stratified block randomization and minimization, potentially resulting in selection bias. Serious baseline covariate imbalances and selection biases often contribute to controversial interpretation of the trial results. The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Trial and the Captopril Prevention Project are two examples. In this article, we propose a new randomization strategy, termed the minimal sufficient balance randomization, which will dually prevent serious imbalances in all important baseline covariates, including both categorical and continuous types, and preserve the randomness of treatment allocation. Computer simulations are conducted using the data from the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Trial. Serious imbalances in four continuous and one categorical covariate are prevented with a small cost in treatment allocation randomness. A scenario of simultaneously balancing 11 baseline covariates is explored with similar promising results. The proposed minimal sufficient balance randomization algorithm can be easily implemented in computerized central randomization systems for large multicenter trials.

[1]  Wenle Zhao,et al.  Quantitative comparison of randomization designs in sequential clinical trials based on treatment balance and allocation randomness , 2012, Pharmaceutical statistics.

[2]  Gerd K Rosenkranz,et al.  The impact of randomization on the analysis of clinical trials , 2011, Statistics in medicine.

[3]  Wenle Zhao,et al.  Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. , 2011, Contemporary clinical trials.

[4]  Vance W Berger,et al.  Minimization, by its nature, precludes allocation concealment, and invites selection bias. , 2010, Contemporary clinical trials.

[5]  T. Kent,et al.  A Matching Algorithm to Address Imbalances in Study Populations: Application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial , 2010, Stroke.

[6]  Stephen Senn,et al.  Comparisons of minimization and Atkinson's algorithm , 2010, Statistics in medicine.

[7]  Andrea Manca,et al.  A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. , 2010, Journal of clinical epidemiology.

[8]  L. Hothorn Statistical issues in drug development (2nd edn). Stephen Senn, John Wiley & Sons Ltd, Chichester, 2007. No. of pages: xix + 498. Price: $130.00. ISBN 978‐0‐470‐01877‐4 , 2009 .

[9]  P. Fayers,et al.  In reply to Berger “don’t test for baseline imbalances unless they are known to be present?” , 2009, Quality of Life Research.

[10]  P. Bath,et al.  Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? , 2009, Stroke.

[11]  Nimodipine BI Orgo,et al.  Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors ? , 2009 .

[12]  J. Burton,et al.  A User's Guide to the NINDS rt-PA Stroke Trial Database , 2008, PLoS medicine.

[13]  J. Saver,et al.  Confirmation of tPA Treatment Effect by Baseline Severity-Adjusted End Point Reanalysis of the NINDS-tPA Stroke Trials , 2007, Stroke.

[14]  E. Steyerberg,et al.  Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study. , 2006, Journal of neurotrauma.

[15]  V. Berger Selection Bias and Covariate Imbalances in Randomized Clinical Trials: Berger/Selection Bias and Covariate Imbalances in Randomized Clinical Trials , 2005 .

[16]  J. Mann NINDS Reanalysis Committee's reanalysis of the NINDS trial. , 2005, Stroke.

[17]  T. Louis,et al.  Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial , 2004, Stroke.

[18]  Anastasia Ivanova,et al.  Minimizing predictability while retaining balance through the use of less restrictive randomization procedures , 2003, Statistics in medicine.

[19]  J. Matthews,et al.  Randomization in Clinical Trials: Theory and Practice; , 2003 .

[20]  S. Pocock,et al.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.

[21]  S. Black,et al.  tPA for acute stroke: balancing baseline imbalances , 2002 .

[22]  L. Kuller,et al.  National guidelines, clinical trials, and quality of evidence. , 2000, Archives of internal medicine.

[23]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[24]  A. Atkinson,et al.  Optimum biased-coin designs for sequential treatment allocation with covariate information. , 1999, Statistics in medicine.

[25]  R. Peto Failure of randomisation by “sealed” envelope , 1999, The Lancet.

[26]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[27]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[28]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[29]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[30]  S. Senn Testing for baseline balance in clinical trials. , 1994, Statistics in medicine.

[31]  D. G. Altman,et al.  Randomisation and baseline comparisons in clinical trials , 1990, The Lancet.

[32]  S J Senn,et al.  Covariate imbalance and random allocation in clinical trials. , 1989, Statistics in medicine.

[33]  C. F. Wu,et al.  Some Restricted randomization rules in sequential designs , 1983 .

[34]  A. Atkinson Optimum biased coin designs for sequential clinical trials with prognostic factors , 1982 .

[35]  D. DeMets,et al.  Fundamentals of Clinical Trials , 1982 .

[36]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[37]  D R Taves,et al.  Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.